Serum syndecan‐1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease

Kyrtsonis, Maria-Christina; Vassilakopoulos, Theodoros P.; Siakantaris, Marina P.; Kokoris, Styliani I.; Gribabis, Despina A.; Dimopoulou, Maria; Angelopoulou, Maria K.; Pangalis, Gerassimos A.

doi:10.1046/j.0902-4441.2003.00205.x

Cited by 30 publications

(33 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surprising was our finding of only statistically limit difference of serum levels of syndecan-1 during complex evaluation of all three prognostic categories according to IPI and at tagetted comparison of index 1 vs 3. This finding appears exceptional with respect to previous numerous studies proved a significant relationship between serum levels of syndecan-1 and levels of β 2 -m 9,38,39,40 and MM prognosis MM 9,39,42,43 . Thus, serum levels of syndecan-1 do not clearly reflect tumour load and renal failure, nor many other biological aspects of the disease 9,10 .…”

contrasting

confidence: 46%

“…Scudla, T. Pika, M. Budikova, P. Petrova, J. Bacovsky, K. Srovnalik, J. Minarik, K. Langova Syndecan-1 is also present in the myeloma microenvironment and acts to promote aggressive myeloma behaviour. Previous studies have demonstrated elevated levels of syndecan-1 in the serum of patients with MM and proved its negative prognostic importance and strong correlation between increased level of serum sCD 138 and tumour mass, as assessed by percent of bone marrow plasmacytosis (BMPC), β 2 -m and MM activity 38,39 . High levels of sCD 138 correlate with tumour mass and have a significant impact on the biology of MM by virtue of its pleiotrophic effects on the cell behaviour 38 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Relationship Between Some Soluble Osteogenic Markers, Angiogenic Cytokines/Other Biological Parameters and the Stages of Multiple Myeloma Evaluated According to the Durie-Salmon and International Prognostic Index Stratification Systems

Scudla¹,

Pika²,

Budíková³

et al. 2009

BIOMED PAP

View full text Add to dashboard Cite

Background:The aim of the present paper was to examine the correlation between serum concentrations of 12 soluble biological markers and stages of myeloma evaluated according to the Durie-Salmon (D-S) and International Prognostic Index (IPI) stratification systems.Methods: We analyzed a non-pretreated group of 179 patients with MM stratified according to D-S and IPI. Serum levels of soluble biological markers were evaluated using ELISA, REA and quantitative sandwich enzymatic immunoassays. The data were analyzed using the Kruskal-Wallis and Mann-Whitney U tests.Results: The staging system according to D-S revealed a highly significant relationship between all stages (I-III) in case of β 2 -m (p<0.0001) and sTK (p<0.001), in sICTP a significant difference was found only in stages II vs III (p<0.001) and I vs III (p<0.001), in case of sCD 138 (syndecan-1) in stages I vs II (p = 0.006) and I vs III (p<0.001), in sVEGF only in stages I vs III (p = 0.006). In substages A vs B we found a significant difference in case of β 2 -m (p<0.0001), sTK (p = 0.041), sICTP (p 0.0001), sOSP (p = 0.008), sHGF (p<0.001), sCD138 (p = 0.001) and sFas (p= 0.001). The relationship between other factors and stages and substages according to D-S appeared nonsignificant. The IPI system showed a highly significant relationship between all 3 categories (1-3) in case of β 2 -m (p<0.001), sTK (p<0.0001) and sICTP (p<0.0001), while in sHGF only in stages 2 vs 3 (p<0.0001) and 1 vs 3 (p<0.0001). In 4 parameters there were only discrete differences in 1 vs 3: sPINP (p= 0.036), sOSP (p= 0.002), sCD 138 (p = 0.03) and sFas (p=0.012), in the remaining markers the analysis was negative.Conclusions: A highly convincing relationship between myeloma stages and serum levels was found only in β 2 -m, sTK, sICTP and partly also in sCD 138 (syndecan-1) and sHGF. More favourable was the IPI stratification system.

show abstract

contrasting

confidence: 46%

mentioning

confidence: 99%

The Relationship Between Some Soluble Osteogenic Markers, Angiogenic Cytokines/Other Biological Parameters and the Stages of Multiple Myeloma Evaluated According to the Durie-Salmon and International Prognostic Index Stratification Systems

Scudla¹,

Pika²,

Budíková³

et al. 2009

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…Literature reports three possible types of results: low levels of OPG, 2-4 high 5-7 and no difference with controls. 8 In MM patients, the levels of RANKL and RANKL/OPG ratio were more than two times higher than controls (p<0.001). This agrees with most other studies.…”

mentioning

confidence: 99%

“…This agrees with most other studies. 4,8,9 OPG shows a tendency to decrease in the advanced clinical stages (NS) and in high grade MBD (S). The lowest OPG level was measured in patients with severe bone lesions (4.26±0.36 pmol/L).…”

mentioning

confidence: 99%

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations

Goranova-Marinova¹,

Goranov²,

Pavlov³

et al. 2007

Haematologica

View full text Add to dashboard Cite

Serum levels of OPG and RANKL and their clinical correlations were analyzed in 66 newly-diagnosed patients with multiple myeloma (MM). RANKL and RANKL /OPG ratios were significantly increased in advanced clinical stages and high grade myeloma bone disease (MBD), while OPG showed a tendency to decrease. Renal failure modified the expression of OPG. RANKL and RANKL/OPG ratios are informative markers for myeloma tumor burden and MBD. Haematologica 2007; 92:1000-1001 OPG/RANKL system is a critical regulator of bone metabolism. A serious imbalance of the system has been found in multiple myeloma (MM). Myeloma cells participate directly in this process. They induce RANKL expression by the bone marrow stromal cells and osteoblasts and most probably produce certain amounts of RANKL themselves. On the other hand myeloma cells bind, internalize and degrade OPG, 1 and inhibit the activity of osteoblasts. While the experimental data for OPG/RANKL system in MM are well-founded, there are few clinical studies on the problem in MM patients.To contribute to the understanding of the role of OPG/RANKL system in myeloma patients, we analyzed the serum levels of OPG and RANKL in 66 newly-diagnosed patients with MM and 32 healthy controls, their expression in the clinical stages and grades of myeloma bone disease (MBD), the influence of renal failure on their levels and their correlations with basic parameters of disease activity. Mean age of the patients was 61.3±9.2 years, 29 males and 37 females. Fifty-three percent were in clinical stage III (ISS). Renal failure (RF) was confirmed in 40.9% and MBD in 84.8% (graded according to the Merlini scale). Analyses were carried out with ELISA (Biomedica, Vienna kits). Statistical analyses were carried out using the Mann-Whitney test, one-way ANOVA and Spearman's correlations. OPG levels were significantly higher in MM patients compared with the controls, but the OPG/creatinin ratio eliminates the difference. Literature reports three possible types of results: low levels of OPG, 2-4 high 5-7 and no difference with controls. 8 In MM patients, the levels of RANKL and RANKL/OPG ratio were more than two times higher than controls (p<0.001). This agrees with most other studies.4,8,9 OPG shows a tendency to decrease in the advanced clinical stages (NS) and in high grade MBD (S). The lowest OPG level was measured in patients with severe bone lesions (4.26±0.36 pmol/L). RANKL and RANKL/OPG ratios significantly increase in advanced clinical stages and in patients with severe bone lesions. They are highest in clinical stage III and in MBD grade 2+3 (Table 1). Reasonably OPG and OPG/creatinin ratios correlate reversely with MBD and bone marrow infiltration. RANKL and RANKL/OPG ratios have positive correlations with the clinical stage, grade of MBD, percentage of bone marrow infiltration and LDH. The strongest correlation was found between the RANKL/OPG ratio and MBD (Table 2). OPG is high in early clinical stages and in patients with minimal bone lesions because, as in the patients with MGUS and beni...

show abstract

“…It is considered to be one of the most important molecules in the multiple myeloma pathobiology 26 . Syndecan-1 appears to be a new important prognostic marker, also a possible parameter for discernment of monoclonal gammopathy of undetermined signifi cance and multiple myeloma 8,9,[27][28][29] . Detected correlation of FLC, K/L ratio and sFas levels is now more of the academical meaning which would be observed.…”

Section: Discussionmentioning

confidence: 99%

The Correlation of Serum Immunoglobulin Free Light Chain Levels and Selected Biological Markers in Multiple Myeloma

Pika¹,

Minařík²,

Schneiderka³

et al. 2008

BIOMED PAP

View full text Add to dashboard Cite

Aims: the presented study is aimed at the evaluation of correlation of free light chains serum levels -kappa, lambda and their relation (K/L ratio) and serum levels of selected biological markers in a group of patients with multiple myeloma examined at the time of the diagnosis.Methods: 102 patients with multiple myeloma were included in this prospective study. Free light chains serum levels were determined by Freelite TM Binding Site system, for determination of serum levels of selected parameters the following methods were used: REA thymidinekinase (TK), RIA (β 2 microglobulin (β 2 m), ICTP, PINP), enzymoimmunoassay (sIL-6R, sVCAM-1, sICAM-1, sOPG) and quantitative enzymatic immunoassay (sHGF, sVEGF, sSyndecan-1 (sSyn-1) a sFas).Results: There was found a correlation in the kappa-group of the dominant kappa chain and serum readings of β 2 m (r = 0.344, p = 0. Conclusions: The study confi rmed mutual correlation of FLC serum levels and the levels of several selected biological markers, in particular β 2 m, TK, ICTP, PINP, sSyn-1 a sFas at time of the diagnosis. It referred to the mutual relation of bone marrow microenvironment, biological qualities of clonal plasmocytes and the intensity of the free light chains production by the tumour cell population.

show abstract

Serum syndecan‐1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease

Abstract: Pretreatment syndecan-1, bFGF and OPG levels were found to be increased at diagnosis. Syndecan-1 and OPG fluctuated according to MM activity. Elevated serum syndecan-1 and bFGF levels predicted short survival.

Cited by 30 publications

References 37 publications

The Relationship Between Some Soluble Osteogenic Markers, Angiogenic Cytokines/Other Biological Parameters and the Stages of Multiple Myeloma Evaluated According to the Durie-Salmon and International Prognostic Index Stratification Systems

The Relationship Between Some Soluble Osteogenic Markers, Angiogenic Cytokines/Other Biological Parameters and the Stages of Multiple Myeloma Evaluated According to the Durie-Salmon and International Prognostic Index Stratification Systems

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations

The Correlation of Serum Immunoglobulin Free Light Chain Levels and Selected Biological Markers in Multiple Myeloma

Contact Info

Product

Resources

About